Sumitomo Pharma Co., Ltd.
DNPUF
Other OTC8.41
USD
- -
- -
ISIN
JP3495000006
Return %
Stock
S&P500
1Y
16.16
18.99
3Y
92.45
64.75
5Y
-58.37
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Toru Kimura
- Full Time Employees
- 3,123
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 6-8, Doshomachi 2-chome Osaka OS Japan 541-0045
- IPO Date
- Jan 17, 2012
- Website
- sumitomo-pharma.com
- Similar Companies
- Business
- Sumitomo Pharma Co., Ltd. is a research and development-oriented pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical products focused on oncology, psychiatry, neurology, and regenerative medicine/cell therapy. The company offers a diverse portfolio including small molecule drugs, regenerative medicine and cell therapy products, pharmaceutical products for medical treatment, and advanced therapies targeting critical disease areas such as cancer, psychiatric and neurological disorders, and rare diseases. Sumitomo Pharma operates globally, with a significant footprint in Japan, North America, and Asia. Founded in 2005 and headquartered in Osaka, Japan, the company has recently expanded its global presence through strategic acquisitions and consolidations, notably acquiring all outstanding shares in Myovant Sciences in April 2023, thereby strengthening its biopharmaceutical capabilities and product pipeline in areas including oncology, urology, women’s health, and rare diseases. In 2024 and 2025, the company has advanced its regenerative medicine and cell therapy business, including clinical trials for iPS cell-derived therapies for conditions such as Parkinson’s disease, retinal pigment epithelium tear, and retinitis pigmentosa, with product sales beginning for RETHYMIC®, a regenerative medicine therapy for pediatric congenital athymia. Additionally, Sumitomo Pharma entered into an agreement transferring its Asia pharmaceutical business operations to Marubeni Corporation in 2025 to focus on accelerating growth in its core markets, notably in the U.S. with leading products such as Gemtesa, Orgovyx, and Myfembree, while continuing to develop novel oncology and regenerative medicine pipeline assets. The company is actively pursuing novel therapies in hematology, including investigational oral small molecules for myelofibrosis and acute leukemia, marked by recent clinical data presentations. Sumitomo Pharma’s strategic focus includes leveraging innovations in pharmaceuticals and regenerative medicine to enhance global healthcare and contribute to patient well-being worldwide.
Sumitomo Pharma America Achieves Key Patient Enrollment Milestone for Pivotal Phase 2 Study of Enzomenib in the Treatment of Relapsed/Refractory Acute Leukemia
Sumitomo Pharma Co., Ltd. (DNPUF) Discusses R&D Progress, Oncology Pipeline, and Advances in Regenerative Medicine and Vaccines Transcript
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment